Andrew Callos, Executive Vice President, Chief Commercial Officer, on June 01, 2026, sold 15,000 shares in Cytokinetics (CYTK) for $1,111,200. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1061983/000106198326000065/xslF345X05/form4.xml
Frank Slootman, Director, on May 29, 2026, sold 437,076 shares in Snowflake (SNOW) for $110,332,853. Following the Form 4 filing with the SEC, Slootman has control over a total of 245,901 common shares of the company, with 38,046 shares held directly and 207,855 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1640147/000140234826000010/xslF345X05/wk-form4_1780358031.xml
Mark Garrett, Director, on May 29, 2026, sold 100,000 shares in Snowflake (SNOW) for $25,000,200. Following the Form 4 filing with the SEC, Garrett has control over a total of 129,811 common shares of the company, with 8,801 shares held directly and 121,010 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1640147/000124621526000001/xslF345X05/wk-form4_1780358006.xml
Chris Koopmans, President and Chief Operating Officer, on June 01, 2026, sold 10,000 shares in Marvell Technology (MRVL) for $2,058,700. Following the Form 4 filing with the SEC, Koopmans has control over a total of 237,392 common shares of the company, with 237,392 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1835632/000162828026039656/xslF345X05/wk-form4_1780360341.xml